-

Forge Biologics to Present at 2021 Cell & Gene Meeting on the Mesa

CEO to discuss company’s AAV gene therapy manufacturing and company achievements over the past 12 months

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., CEO, President and Co-Founder, will discuss Forge’s robust AAV manufacturing solutions, proprietary technology advancements, and clinical development during a company presentation at Cell & Gene Meeting on the Mesa on October 12 at 5:00 p.m. PT.

Dr. Miller will also join a panel of gene therapy experts for a discussion on “Dosing & Redosing in Gene Therapy,” October 14 at 11:00 a.m. PT.

The conference will take place October 12-14, 2021, at the Park Hyatt Aviara, in Carlsbad, California. To learn more about the event and registration, please visit: https://meetingonthemesa.com.

Forge will be taking meetings during Meeting on the Mesa. Please contact John Maslowski, Chief Commercial Officer, at CD@forgebiologics.com if you are interested in connecting and learning more about how Forge’s manufacturing solutions can support your gene therapy program.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 175,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
medicalaffairs@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Forge Biologics


Release Summary
Forge to Present at 2021 Cell & Gene Meeting on the Mesa
Release Versions

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
medicalaffairs@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Social Media Profiles
More News From Forge Biologics

Avista Therapeutics and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership

PITTSBURGH & COLUMBUS, Ohio--(BUSINESS WIRE)--Avista Therapeutics (“Avista”), a pre-clinical-stage biotechnology company developing novel AAV capsids with high efficacy and unique tropisms into innovative gene therapies for rare ophthalmic conditions, and Forge Biologics, (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to advance the development and manufacturing of AVST-101, Avista’s lead gene...

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva* pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes (T2D). "We developed our FUEL™ platform to provide developers like Fractyl with a more efficient and scalable manufacturing solution to help...

Forge Biologics Announces Eight Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025 in New Orleans, Louisiana. The presentations include two technical session presentations, an oral presentation, and five scientific posters focused on Forge’s FUEL™ pl...
Back to Newsroom